Fingerprint
Dive into the research topics of 'Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically